Evidence map›Paper›PMID 29885537›Full record

ReviewAutoimmunity reviews2018

Impact of obesity on autoimmune arthritis and its cardiovascular complications.

Katrien Van Raemdonck, Sadiq Umar, Zoltán Szekanecz, Ryan K Zomorrodi, Shiva Shahrara

Open access · greenAbstract readReview
In one paragraph

Review in Autoimmunity reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Lipid-Lowering and Anti-Inflammatory Effects ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Emerging Roles of Adipose Tissue in the Pathogenesis of Psoriasis and Atopic Dermatitis in Obesity.JID innovations : skin science from molecules to population health · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Katrien Van RaemdonckJesse Brown VA Medical Center, Chicago, IL 60612, United States; Department of Medicine, Division of Rheumatology, University of Illinois at Chicago, IL 60612, United States.
Sadiq UmarJesse Brown VA Medical Center, Chicago, IL 60612, United States; Department of Medicine, Division of Rheumatology, University of Illinois at Chicago, IL 60612, United States.
Zoltán SzekaneczDepartment of Rheumatology, Institute of Medicine, University of Debrecen Faculty of Medicine, Nagyerdei Str 98, Debrecen H-4004, Hungary.
Ryan K ZomorrodiDepartment of Medicine, Division of Rheumatology, University of Illinois at Chicago, IL 60612, United States.
Shiva ShahraraJesse Brown VA Medical Center, Chicago, IL 60612, United States; Department of Medicine, Division of Rheumatology, University of Illinois at Chicago, IL 60612, United States. Electronic address: shahrara@uic.edu.
University of Illinois Chicago · USUniversity of Debrecen · HU

Funding

Engineering a unique antibody for patients with RAR41AI147697 · NIAID · ABWIZ BIO, INC. · PI MARUYAMA, TOSHIAKI, SHAHRARA, SHIVA · 2020 to 2021
$600k
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapyR43AG057312 · NIA · MICROBIOTIX, INC · PI ARON, ZACHARY DAVID, SHAHRARA, SHIVA · 2017 to 2018
$433k
Identifying a novel link between two potent proangiogenic cascades in RAR03AR065778 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHAHRARA, SHIVA · 2014 to 2016
$239k
BLRD VA I01 BX002286NIAID NIH HHS R41 AI147697NIAMS NIH HHS R03 AR065778NIA NIH HHS R43 AG057312
6 · The paper itself

Abstract

Obesity can instigate and sustain a systemic low-grade inflammatory environment that can amplify autoimmune disorders and their associated comorbidities. Metabolic changes and inflammatory factors produced by the adipose tissue have been reported to aggravate autoimmunity and predispose the patient to cardiovascular disease (CVD) and metabolic comorbidities. Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are autoimmune arthritic diseases, often linked with altered body mass index (BMI). Severe joint inflammation and bone destruction have a debilitating impact on the patient's life; there is also a staggering risk of cardiovascular morbidity and mortality. Furthermore, these patients are at risk of developing metabolic symptoms, including insulin resistance resulting in type 2 diabetes mellitus (T2DM). In addition, arthritis severity, progression and response to therapy can be markedly affected by the patient's BMI. Hence, a complex integrative pathogenesis interconnects autoimmunity with metabolic and cardiovascular disorders. This review aims to shed light on the network that connects obesity with RA, PsA, systemic lupus erythematosus and Sjӧgren's syndrome. We have focused on clarifying the mechanism by which obesity affects different cell types, inflammatory factors and traditional therapies in these autoimmune disorders. We conclude that to further optimize arthritis therapy and to prevent CVD, it is imperative to uncover the intricate relation between obesity and arthritis pathology.

Indexed as

Arthritis, RheumatoidAutoimmune DiseasesCardiovascular DiseasesHumansObesityCardiovascular diseaseInflammationMetabolic syndromeObesityPsARA

Identifiers

PMID29885537
PMCPMC9996646
OpenAlexW2806898285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.